蛛网膜下腔出血与脑出血患者脑脊液中膜颗粒结合CD133的变化
该研究连续纳入47例蛛网膜下腔出血(SAH)或脑出血(ICH)患者,与14例健康对照比较脑脊液中膜颗粒结合CD133含量。SAH组和ICH组CD133均显著高于对照组,且住院期间下降;SAH组CD133持续升高与3个月功能预后不良相关。
要点
- SAH组和ICH组脑脊液膜颗粒结合CD133均显著高于健康对照组。
- SAH组和ICH组CD133水平在住院前7天内均下降。
- SAH组CD133持续升高与3个月功能预后不良相关。
核心结论
- SAH和ICH患者脑脊液中膜颗粒结合CD133水平较健康者显著升高,且住院期间下降;SAH患者第一周内CD133阳性膜颗粒持续升高可能代表功能预后不良的潜在替代指标。
研究设计与样本
- 连续纳入47例SAH或ICH患者,与14例健康对照比较;脑脊液经差速超速离心后行凝胶电泳分离膜颗粒组分,用鼠单克隆抗体80B258免疫印迹检测CD133,以人Caco-2细胞提取物为标准曲线阳性对照进行定量。
主要发现
- 膜颗粒相关CD133免疫反应量:健康对照组6.3 ± 0.5 ng(n = 14),SAH组38.2 ± 6.6 ng(n = 18)和ICH组61.3 ± 11.0 ng(n = 29),均p < 0.001。
- 入院至第5-7天CD133变化量:SAH组第5-7天24.6 ± 10.1 ng(p = 0.06);ICH组第5-7天25.0 ± 4.8 ng(p = 0.002)。
- ICH组入院至第5-7天CD133变化量与临床结局无关:mRS 0-3分 -30.9 ± 12.8 ng vs mRS 4-6分 -21.8 ± 10.7 ng,p = 0.239。
- SAH组CD133持续升高与发病后3个月功能预后不良相关:mRS 0-2分 -29.9 ± 8.1 ng vs mRS 3-6分 7.6 ± 20.3 ng,p = 0.027。
- 数据以均值 ± 均值标准误(SEM)表示。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have demonstrated that human CSF contains membrane particles carrying the stem cell antigenic marker CD133 (prominin-1). Here, the authors analyzed the variation of the amount of these CD133-positive particles in the CSF of patients with subarachnoid hemorrhage (SAH) and intracerebral hemorrhage (ICH). METHODS: Consecutive CSF samples from 47 patients with SAH or ICH were compared to 14 healthy control patients. After differential ultracentrifugation of CSF, the membrane particle fraction was separated on gel electrophoresis and its CD133 content was probed by immunoblotting using the mouse monoclonal antibody 80B258 directed against human CD133. The antigen-antibody complexes were detected by chemiluminescence reagents and quantified using human Caco-2 cell extract as positive control with a standardized curve. RESULTS: As compared to healthy controls (6.3 ± 0.5 ng of bound CD133 antibody; n = 14), the amount of membrane particle-associated CD133 immunoreactivities was significantly elevated in patients with SAH and ICH (38.2 ± 6.6 ng and 61.3 ± 11.0 ng [p < 0.001] for SAH [n = 18] and ICH [n = 29], respectively). In both groups the CD133 level dropped during the first 7 days (i.e., day 5-7: SAH group, 24.6 ± 10.1 ng [p = 0.06]; ICH group, 25.0 ± 4.8 ng [p = 0.002]). Whereas changes in the amount of CD133-positive membrane particles between admission and day 5-7 were not associated with clinical outcomes in patients with ICH (modified Rankin Scale [mRS] scores 0-3, -30.9 ± 12.8 ng vs mRS scores 4-6, -21.8 ± 10.7 ng; p = 0.239), persistent elevation of CD133 in patients with SAH was related to impaired functional outcome 3 months after ictus (mRS scores 0-2, -29.9 ± 8.1 ng vs mRS scores 3-6, 7.6 ± 20.3 ng; p = 0.027). These data are expressed as the mean ± standard error of the mean (SEM). CONCLUSIONS: Levels of membrane particle-associated CD133 in the CSF of patients with SAH and ICH are significantly increased in comparison to healthy patients, and they decline during the hospital stay. Specifically, the persistent elevation of CD133-positive membrane particles within the first week may represent a possible surrogate measure for impaired functional outcome in patients with SAH.
引用
- Bobinger T, Roeder SS, Spruegel MI, et al. Variation of membrane particle-bound CD133 in cerebrospinal fluid of patients with subarachnoid and intracerebral hemorrhage. J Neurosurg. 2020. PMID: 31978876. doi:10.3171/2019.11.JNS191861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。